Health-Related Quality of Life (HRQoL) in Patients with Relapsed/Refractory Follicular Lymphoma (R/R FL) Treated with Zanubrutinib plus Obinutuzumab Versus Obinutuzumab Monotherapy: The Rosewood Trial

被引：0

作者：

Trotman, Judith ^{[1
]}

Zinzani, Pier Luigi ^{[2
,3
]}

Song, Yuqin ^{[4
]}

Delarue, Richard ^{[5
]}

Barnes, Gisoo ^{[6
,7
]}

Kim, Pil ^{[6
,7
]}

Ivanova, Elena ^{[6
,7
]}

Tang, Boxiong ^{[6
,7
]}

Mayer, Jiri ^{[8
,9
]}

De Oliveira, Ana C. ^{[10
]}

Assouline, Sarit ^{[11
]}

Flowers, Christopher R. ^{[12
]}

机构：

[1] Univ Sydney, Concord Repatriat Gen Hosp, Sydney, NSW, Australia

[2] Univ Bologna, IRCCS Azienda Osped Univ Bologna, Ist Ematol Seragnoli, Bologna, Italy

[3] Univ Bologna, Dipartimento Sci Med & Chirurg, Bologna, Italy

[4] Peking Univ Canc Hosp & Inst, Beijing, Peoples R China

[5] BeiGene Switzerland GmbH, Basel, Switzerland

[6] BeiGene Shanghai Co Ltd, Shanghai, Peoples R China

[7] BeiGene USA Inc, San Mateo, CA USA

[8] Masaryk Univ, Dept Internal Med Hematol & Oncol, Brno, Czech Republic

[9] Univ Hosp, Brno, Czech Republic

[10] Univ Barcelona, Dept Clin Hematol, Inst Catala Oncol, Hosp Duran & Reynals,IDIBELL, Barcelona, Spain

[11] McGill Univ, Jewish Gen Hosp, Montreal, PQ, Canada

[12] MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX USA

来源：

关键词：

D O I：

10.1182/blood-2023-181195

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4